Latest Commercialisation Strategy News

Page 3 of 14
Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.
Ada Torres
Ada Torres
27 Feb 2026
Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.
Ada Torres
Ada Torres
26 Feb 2026
Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.
Ada Torres
Ada Torres
26 Feb 2026
Firebird Metals has locked in exclusive global rights to five critical LMFP patents, solidifying its position in the lithium-ion battery materials market and paving the way for its Australian Demonstration Plant.
Maxwell Dee
Maxwell Dee
26 Feb 2026
Papyrus Australia Limited reported a reduced half-year loss and marked a significant commercial milestone with a $4.2 million supply contract, advancing its transition from technology development to early-stage commercialisation.
Maxwell Dee
Maxwell Dee
24 Feb 2026
Li-S Energy narrows its loss to $1.21 million in H1 2026, propelled by a $7.8 million ARENA grant and key manufacturing milestones including Australia’s first lithium metal foil production line. Strategic defence and aerospace partnerships bolster its commercialisation drive.
Maxwell Dee
Maxwell Dee
20 Feb 2026
Temas Resources has inked a Letter of Intent to validate its patented Regenerative Chloride Leach technology on a major refractory gold deposit, paving the way for a joint venture to commercialise the platform in Western North America.
Maxwell Dee
Maxwell Dee
16 Feb 2026
Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.
Ada Torres
Ada Torres
6 Feb 2026
GCM Corporation is advancing its commercialisation strategy with multiple prototypes across key global markets and sectors, aiming for revenue in the first half of 2026.
Sophie Babbage
Sophie Babbage
4 Feb 2026
ClearVue Technologies advances its building-integrated solar tech with new product breakthroughs and global commercial projects, while strengthening its financial footing and board expertise.
Victor Sage
Victor Sage
30 Jan 2026
4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.
Ada Torres
Ada Torres
30 Jan 2026
Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.
Ada Torres
Ada Torres
30 Jan 2026